Skip to main content
. 2022 Apr 26;40:38–45. doi: 10.1016/j.euros.2022.03.012

Table 4.

Treatment-related adverse events of grade ≥3a

Grade AE related to ILIXA/SUN (N = 58) SUN (N = 30) Total (N = 88)
n (%) n (%) n (%)
3 SUN 13 (22.4) 5 (16.7) 18 (20.5)
ILIXA 2 (3.4) NA 2 (2.3)
4 SUN 1 (1.7) 2 (6.7) 3 (3.4)
ILIXA 0 (0.0) NA 0 (0.0)
5 SUN 0 (0.0) 1 (3.3) 1 (1.1)
ILIXA 0 (0.0) NA 0 (0.0)

AE = adverse event; ILIXA = ilixadencel; NA = not available; SUN = sunitinib.

a

Common Terminology Criteria for Adverse Events version 5.0.